UY33270A - Sales cristalinas de un potente inhibidor del hcv - Google Patents

Sales cristalinas de un potente inhibidor del hcv

Info

Publication number
UY33270A
UY33270A UY0001033270A UY33270A UY33270A UY 33270 A UY33270 A UY 33270A UY 0001033270 A UY0001033270 A UY 0001033270A UY 33270 A UY33270 A UY 33270A UY 33270 A UY33270 A UY 33270A
Authority
UY
Uruguay
Prior art keywords
powerful
hcv inhibitor
crystal salts
hcv
salts
Prior art date
Application number
UY0001033270A
Other languages
English (en)
Inventor
Bing-Shiou
Yip Ka
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43778392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33270(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY33270A publication Critical patent/UY33270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Esta invención se refiere a nuevas formas salinas de tris(hidroximetil)aminometano,colina y N-metil-D-glucamina del siguiente Compuesto (1) y a métodos para la preparación de las mismas, a sus composiciones farmacéuticas, y a su uso en el tratamiento de la infección por el virus de la Hepatitis C (HCV):
UY0001033270A 2010-03-11 2011-03-10 Sales cristalinas de un potente inhibidor del hcv UY33270A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31279110P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
UY33270A true UY33270A (es) 2011-10-31

Family

ID=43778392

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033270A UY33270A (es) 2010-03-11 2011-03-10 Sales cristalinas de un potente inhibidor del hcv

Country Status (17)

Country Link
US (3) US8530497B2 (es)
EP (1) EP2545049B1 (es)
JP (2) JP5687291B2 (es)
KR (1) KR101756632B1 (es)
CN (2) CN102844315B (es)
AR (1) AR080494A1 (es)
AU (1) AU2011224311B2 (es)
BR (1) BR112012022812A2 (es)
CA (1) CA2792684C (es)
CL (1) CL2012002362A1 (es)
EA (1) EA021805B1 (es)
IL (1) IL221198A (es)
MX (1) MX2012009964A (es)
NZ (1) NZ601563A (es)
TW (1) TW201200511A (es)
UY (1) UY33270A (es)
WO (1) WO2011112761A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2331538T1 (sl) * 2008-09-16 2014-06-30 Boehringer Ingelheim International Gmbh Kristalinične oblike 2-tiazolil-4-kinolinil-oksi derivata, učinkovitega inhibitorja HCV
WO2010033443A1 (en) 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
CN102596201A (zh) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
JP5677645B2 (ja) 2011-10-21 2015-02-25 アッヴィ・インコーポレイテッド 少なくとも２種の直接作用型抗ウイルス剤、およびリバビリンを含むがインターフェロンを含まない、ｈｃｖを治療するための方法
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
CA2902569A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibitors of hepatitis c virus
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
WO2018096517A1 (en) * 2016-11-28 2018-05-31 Parayil Sarin Novel organic crystalline salt of haloacetic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0649651T3 (da) 1993-09-28 2001-02-26 Scherer Gmbh R P Fremstilling af bløde gelatinekapsler
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
NZ544076A (en) * 2003-05-21 2009-04-30 Boehringer Ingelheim Int Hepatitis C inhibitor compounds
EP1753775B1 (en) * 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
SI2331538T1 (sl) 2008-09-16 2014-06-30 Boehringer Ingelheim International Gmbh Kristalinične oblike 2-tiazolil-4-kinolinil-oksi derivata, učinkovitega inhibitorja HCV
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor

Also Published As

Publication number Publication date
AU2011224311A1 (en) 2012-08-23
CN102844315A (zh) 2012-12-26
EP2545049A1 (en) 2013-01-16
CN104945396B (zh) 2018-02-27
AR080494A1 (es) 2012-04-11
JP2015143223A (ja) 2015-08-06
CN104945396A (zh) 2015-09-30
WO2011112761A1 (en) 2011-09-15
US8530497B2 (en) 2013-09-10
JP5687291B2 (ja) 2015-03-18
US20120059033A1 (en) 2012-03-08
US9382240B2 (en) 2016-07-05
EP2545049B1 (en) 2015-10-14
NZ601563A (en) 2013-12-20
CL2012002362A1 (es) 2013-01-11
US20150166530A1 (en) 2015-06-18
KR20130009966A (ko) 2013-01-24
IL221198A (en) 2017-01-31
KR101756632B1 (ko) 2017-07-11
BR112012022812A2 (pt) 2018-05-15
CA2792684C (en) 2018-07-31
EA021805B1 (ru) 2015-09-30
US20130317061A1 (en) 2013-11-28
MX2012009964A (es) 2012-09-21
AU2011224311B2 (en) 2014-08-14
IL221198A0 (en) 2012-10-31
TW201200511A (en) 2012-01-01
EA201201277A1 (ru) 2013-04-30
CA2792684A1 (en) 2011-09-15
CN102844315B (zh) 2015-05-20
JP2013522221A (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
UY33270A (es) Sales cristalinas de un potente inhibidor del hcv
UY32119A (es) Formas cristalinas de un potente inhibidor de hcv
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
ECSP17084267A (es) Pirazolo[1,5—a]pirimidinas como agentes antivirales
CO6680607A2 (es) Métodos para la preparación de profármacos de fosforamidato diastereoméricamente puros
ECSP12012104A (es) Inhibidores de virus flaviviridae
CO6811860A2 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20160686A1 (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
UY34234A (es) Inhibidores de la replicación de los virus de la gripe
CR20140548A (es) Derivados de aril-sultamo como moduladores de rorc
CO7240410A2 (es) Inhibidores macrocíclicos de virus flaviviridae
CL2014001599A1 (es) Compuestos derivados de nucleosidos sustituidos en 4’-azido, 3’-fluoro o sus sales, como inhibidores de la replicacion del rna del vhc; composicion farmaceutica que los comprende; y su uso para el tratamiento o la profilaxis de la infeccion por el virus de la hepatitis c (vhc).
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
DOP2013000017A (es) Procesos para preparar compuestos antivirales
DOP2014000133A (es) Triazolopiridinas sustituidas
UY31132A1 (es) Compuestos quimicos
CO6561783A2 (es) Inhibidores del virus flaviviridae
UY33897A (es) Inhibidores del virus de la hepatitis c
UY34066A (es) Inhibidores del virus de la hepatitis c
GT201300254A (es) Triazolopiridinas
DOP2014000081A (es) Compuestos y procedimientos para mejorar las respuestas inmunitarias innatas
EA201491442A1 (ru) Твердые формы, содержащие ингибиторы ns5a вируса гепатита с, их композиции и их применение
CR20110524A (es) Proceso para preparar compuestos antivirales
AR090830A1 (es) Cocristales de metalaxil y protioconazol y procedimientos para la fabricacion y el uso de los mismos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191217